Management ChangeSep 29, 2026, 07:31 AM
Aquestive Therapeutics Appoints Richard Daly to Board of Directors
AI Summary
Aquestive Therapeutics, Inc. announced the election of Richard J. Daly to its Board of Directors, effective October 14, 2026. Mr. Daly, an experienced life sciences executive, will serve as a Class I director, and his appointment increases the Board size to eight members. He will receive an initial award of 57,000 stock options as part of the non-employee director compensation program. The company highlighted Mr. Daly's extensive experience in commercial and operating roles within the biopharmaceutical industry.
Key Highlights
- Richard J. Daly elected as a director, effective October 14, 2026.
- Mr. Daly will serve as a Class I director with a term expiring at the Company’s 2028 Annual Meeting of Stockholders.
- The Board of Directors size increased from seven to eight members.
- Mr. Daly will be granted an initial award of 57,000 stock options.
- Mr. Daly is a life sciences executive with over 30 years of leadership experience.
Price Impact
More from AQST